Literature DB >> 10769106

Secondary amyloidosis: a severe complication of ankylosing spondylitis. Two case-reports.

M Kovacsovics-Bankowski1, P Zufferey, A K So, J C Gerster.   

Abstract

STUDY
OBJECTIVE: To report two cases of amyloidosis secondary to ankylosing spondylitis. PATIENTS AND
RESULTS: Of the 47 ankylosing spondylitis patients who have received follow-up at our department over the last few years, two have developed AA amyloidosis. Both have extremely severe, long-standing joint disease, with virtually complete spinal ankylosis and destructive peripheral arthritis of the hips and wrists; one also has tarsal joint destruction. Renal dysfunction was the first manifestation of amyloidosis in both cases. One patient required chronic hemodialysis and developed peritonitis due to colonic perforation, probably at a site of amyloid deposition.
CONCLUSIONS: Secondary amyloidosis is a rare complication of ankylosing spondylitis that can cause severe renal and gastrointestinal complications. No treatment capable of clearing established amyloid deposits is available to date.

Entities:  

Mesh:

Year:  2000        PMID: 10769106

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  3 in total

1.  Colonic Perforation as Initial Presentation of Amyloid Disease: Case Report and Literature Review.

Authors:  A Ussia; S Vaccari; A Lauro; A Caira; M L Tardio; O Leone; I R Marino; V D'Andrea; M Cervellera; V Tonini
Journal:  Dig Dis Sci       Date:  2020-02       Impact factor: 3.199

2.  The burden of amyloidosis on the gastrointestinal tract of an ankylosing spondylitis patient.

Authors:  Levent Ozçakar; Seyfettin Köklü; Bayram Kaymak; Sedef Kuran; Zişan Sakaoğullari
Journal:  Clin Rheumatol       Date:  2003-10-16       Impact factor: 2.980

3.  Spondyloarthritis Patients Suffer Increased Risk of Renal Complications Compared With General Population: A Retrospective Observational Study.

Authors:  Min Xiao; Qing Lv; Yanli Zhang; Liudan Tu; Mingcan Yang; Zhiming Lin; Zetao Liao; Yutong Jiang; Xuqi Zheng; Xiaomin Li; Qiujing Wei; Shuangyan Cao; Jieruo Gu
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.